4:48 PM
 | 
Sep 05, 2013
 |  BC Extra  |  Clinical News

GSK's MAGE-A3 misses in Phase III melanoma trial

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said intramuscular MAGE-A3 given after surgical removal of a patient's tumors missed the co-primary endpoint of improving disease-free survival (DFS) vs. placebo n the Phase III DERMA trial to treat melanoma-associated antigen A3 ( MAGEA3)-positive, resected melanoma. Based on...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >